10
3
150
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1604 |
Tiratricol
3,3',5-Triiodothyroacetic acid,替拉曲可 |
Thyroid hormone receptor(THR) | Endocrinology/Hormones |
Tiratricol (3,3',5-Triiodothyroacetic acid) 是 T3 和 T4 甲状腺激素的代谢物;促进高脂血症、局部脂肪营养不良和肥胖。它已用于研究 Allan-Herndon-Dudley 综合征治疗的试验。 | |||
T1669 |
Liothyronine sodium
3,3',5-Triiodo-L-thyronine sodium,Triostat,T3 Sodium salt,三碘代甲状腺素钠盐,Sodium L-3,3',5-triiodothyronine,Cytomel |
Thyroid hormone receptor(THR) | Endocrinology/Hormones |
Liothyronine sodium (3,3',5-Triiodo-L-thyronine sodium) 是甲状腺激素,能够结合并激活 β1 甲状腺激素受体。 | |||
T25411 |
Fenclofenac
R 67408,Rx 67408,R67408,Flenac |
||
Fenclofenac is a non-steroidal anti-inflammatory agent that competitively supresses the binding of thyroxine(T4) and triiodothyronine (T3) by thyroxine-binding globulin(TBG). | |||
T31475 |
Dihydropteroyl hexaglutamate
|
||
Dihydropteroyl hexaglutamate is a link binding together sub-structures of the tail of Escherichia coli bacteriophage T4. | |||
T82879 |
Biotin-hexanamide-(L-Thyroxine)
|
||
Biotin-hexanamide-(L-Thyroxine)为生物素化L-Thyroxine化合物。该化合物中的L-Thyroxine(即Levothyroxine;T4)作为一种合成甲状腺激素,广泛用于甲状腺功能减退症的研究中。 | |||
T15699 |
L-Thyroxine sodium salt pentahydrate
左旋甲状腺素钠五水合物,Sodium levothyroxine pentahydrate,Levothyroxine,L-甲状腺素钠五水合物 |
Thyroid hormone receptor(THR) | Endocrinology/Hormones |
L-Thyroxine sodium salt pentahydrate (Levothyroxine) 是一种合成的甲状腺激素,用于甲状腺功能减退症的研究。 | |||
T32500 |
L6Y
TTR stabilizer L6 |
||
L6Y is a transthyretin (TTR) stabilizer which binds to the T4 binding pocket of TTR and prevents the dissociation of TTR to monomer. | |||
T79925 |
T4 UvsX Recombinase
|
DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
T4 UvsX Recombinase 促进双链DNA模板上DNA复制的启动,通过催化模板DNA与同源单链DNA引物间的突触形成。此酶显著增强了T4 DNA聚合酶全酶在线性单链DNA模板上进行的回跳(发夹引物)DNA合成反应。 | |||
T69555 |
XUN49524
|
||
XUN49524 also known as Vezf1-IN-T4, is an inhibitor of the pro-angiogenic activity of the zinc finger transcription factor Vezf1. XUN49524 was first reported in Molecules (2018), 23(7), 1615/1-1615/15 . This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming). | |||
T80621 |
Semzuvolimab
UB421 |
||
Semzuvolimab是靶向T细胞表面抗原T4/Leu-3,即p55 (CD4)的鼠IgG1κ类抗体。该CD4抗体具备中和HIV感染的能力,潜在用于抑制HAART稳定型HIV感染。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36715 |
Tetrac
Tetraiodothyroacetic acid,3,3',5,5'-Tetraiodothyroacetic acid |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tetrac (Tetraiodothyroacetic acid)是L-甲状腺素(T4)的衍生物,是一种甲状腺整合素受体拮抗剂。Tetrac通过阻断EGFR介导的结直肠癌细胞信号传导来诱导抗增殖。Tetrac 可阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3)在细胞表面甲状腺素整合素 αvβ3 受体上的作用。Tetra 具有抗血管生成、抗肿瘤活性和促凋亡活性。 | |||
T2760 |
(S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate
Iodogorgoic acid,apothyrin,jodgorgon,3,5-Diiodotyrosine Dihydrate,双碘酪氨酸 |
Others; Endogenous Metabolite | Metabolism; Others |
(S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate (jodgorgon) 是内源性代谢产物的一种。 | |||
T4893 |
Spermidine
N-(3-Aminopropyl)-1,4-diaminobutane,亚精胺,N-(4-Aminobutyl)-1,3-diaminopropane |
Endogenous Metabolite | Metabolism |
Spermidine (N-(3-Aminopropyl)-1,4-diaminobutane) 能够维持细胞膜稳定性,提高抗氧化酶活性,改善光系统 II 以及相关基因表达。它结合并激活 NMDA,并已显示以浓度依赖性方式增强 NMDA 诱导的电流。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00929 |
Serpin B3 Protein, Human, Recombinant (N-His)
SCCA-1,Serpin B3,serine (or cysteine) proteina<... |
Human | E. coli |
Serpin B3 Protein, Human, Recombinant (N-His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 40-55 KDa and the accession number is P29508. | |||
TMPJ-00928 |
Serpin B3 Protein, Human, Recombinant (C-His)
SCCA1,serpin peptidase inhibitor, cla<... |
Human | HEK293 Cells |
Serpin B3 Protein, Human, Recombinant (C-His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 41-50 KDa and the accession number is P29508. | |||
TMPY-02712 |
Serpin B3 Protein, Human, Recombinant (His)
T4-A,HsT1196,serpin peptidase inh... |
Human | Baculovirus Insect Cells |
SERPINB3, also known as SCCA-1, belongs to the serpin family. Serpins are a group of proteins with similar structures that were first identified as a set of proteins able to inhibit proteases. The acronym serpin was originally coined because many serpins inhibit chymotrypsin-like serine proteases. SERPINB3 is expressed in some hepatocellular carcinoma (at protein level). Its expression is closely related to cellular differentiation in both normal and malignant squamous cells. It seems to also be... | |||
TMPH-00525 |
DsDNA-binding protein A Protein, Enterobacteria phage T4, Recombinant (His & Myc)
dsbA,rpbB,Double-stranded DNA-bin... |
Enterobacteria phage T4 | E. coli |
May play a role in transcription of several T4 genes. Binds double-stranded DNA and interacts preferentially with T4 late promoter regions. DsDNA-binding protein A Protein, Enterobacteria phage T4, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 17.8 kDa and the accession number is P13320. | |||
TMPY-02779 |
Thyroid peroxidase Protein, Human, Recombinant (S257A & P725T, His)
thyroid peroxidase,MSA,TPX,TDH2A |
Human | Baculovirus Insect Cells |
Thyroid peroxidase is a membrane-bound glycoprotein which belongs to the peroxidase family, XPO subfamily. It contains 1 EGF-like domain and 1 Sushi (CCP/SCR) domain. Thyroid Peroxidase represents one of the main autoantigenic targets in autoimmune thyroid disease of humans. It used to be taken as the formerly so-called `microsomal antigen` several years ago. As an integral membrane glycoprotein it is restricted to the apical plasma membrane of the follicular epithelial cells and comprises two i... | |||
TMPH-00524 |
ATP-dependent DNA helicase dda Protein, Enterobacteria phage T4, Recombinant (His)
ATP-dependent DNA helicase dd... |
Enterobacteria phage T4 | E. coli |
DNA helicase that stimulates viral DNA replication and recombination. Plays a role in T4 DNA replication initiation by selecting and activating DNA origins. Acts by dissociating and reassociating with the DNA molecule being unwound. Unwinds DNA as a monomer in a 5'-to-3' direction at a rate of 250 bp/s and can efficiently displace proteins from the DNA. ATP-dependent DNA helicase dda Protein, Enterobacteria phage T4, Recombinant (His) is expressed in E. coli expression system with N-6xHis tag. T... | |||
TMPH-03385 |
Thyroglobulin Protein, Rat, Recombinant (His & SUMO)
|
Rat | E. coli |
Acts as a substrate for the production of iodinated thyroid hormones thyroxine (T4) and triiodothyronine (T3). The synthesis of T3 and T4 involves iodination of selected tyrosine residues of TG/thyroglobulin followed by their oxidative coupling. Following TG re-internalization and lysosomal-mediated proteolysis, T3 and T4 are released from the polypeptide backbone leading to their secretion into the bloodstream. One dimer produces 7 thyroid hormone molecules. Thyroglobulin Protein, Rat, Recombin... | |||
TMPJ-01296 |
SULT4A1 Protein, Human, Recombinant
hBR-STL,SULTX3,Nervous System Sulfotransfera |
Human | E. coli |
Sulfotransferase 4A1 (ST4A1) is a member of the Sulfotransferase 1 family. ST4A1 is highly expressed in the cerebral cortex and frontal lobe, but no expression is detected in the pancreas. ST4A1 is a brain-specific sulfotransferase believed to be involved in the metabolism of neurotransmitters. ST4A1 acts on catecholamines and T4 in a manner that may not involve sulfonation. ST4A1 may have a role in the metabolism of drugs and neurotransmitters in the CNS. In addition, ST4A1 is related to schizo... | |||
TMPK-00874 |
Thyroid Peroxidase Protein, Mouse, Recombinant (His)
MK-CSF,MGDF,ML,MPLLG,THPO,TPOMKCSF,Thrombopoietin,MKCSF,MGDF... |
Mouse | HEK293 Cells |
Thyroid peroxidase, also called thyroperoxidase (TPO) or iodide peroxidase that encodes a 933 amino-acid residue (aa) molecule with a single membrane-spanning region. Thyroid peroxidase plays a key role in thyroid hormone synthesis by catalyzing both the iodination of tyrosine residues to form monoiodotyrosine (MIT) and diiodotyrosine (DIT) residues and the coupling of iodotyrosine residues in Tg, resulting in the formation of T3 and T4. It is a frequent epitope of autoantibodies in autoimmune t... | |||
TMPY-06821 |
THRB Protein, Human, Recombinant (His)
THRB1,GRTH,THR1,ERBA2,C-ERBA-2,THRB2,thyro... |
Human | E. coli |
Thyroid hormone receptor beta (THRB), also known as TRbeta and NR1A2, belongs to the nuclear hormone receptor family. Featuring an N-terminal transactivation domain, a central DNA-binding domain, and a hormone/ligand-binding domain, THRB isoform 1/2 expression localizes predominately to the liver and pituitary, respectively. THRB regulates the feedback of T3-dependent thyrotropin-stimulating hormone (TSH) transcription in the pituitary by binding to thyroid hormone (TH) response elements present... | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kra |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTP... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01448 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (E. coli, His & Avi)
MHC,LAGE-2,NY-ESO-1,ESO1CTAG,MY-ESO-1,CT |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01467 |
HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer Protein, Human, MHC (His & Avi)
HPV16,E6,Human papillomavirus typ... |
Human | HEK293 Cells |
Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPA |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01444 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01474 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi)
|
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01470 |
HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi)
MAGE-A4 or MAGE-A8,M... |
Human | HEK293 Cells |
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01417 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Alpha-1-fetoprotein,HPAFP,A |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01446 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi)
MAGE1,MAGE1A,MAGE-1 ... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01481 |
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
svn 2B,svn-2B,Survivin-2B |
Human | HEK293 Cells |
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. | |||
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01530 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LMP-2,PSMB9,LMP2,Macropain cha |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01513 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT6.1,LAGE2A,MHC,CTAG1B,CTA |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,E... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
------------------------ 更多 ------------------------ |